4.7 Article

Rosa davurica Pall. improves DNCB-induced atopic dermatitis in mice and regulated TNF-Alpa/IFN-gamma-induced skin inflammatory responses in HaCaT cells

Journal

PHYTOMEDICINE
Volume 91, Issue -, Pages -

Publisher

ELSEVIER GMBH
DOI: 10.1016/j.phymed.2021.153708

Keywords

Rosa davurica Pall.; atopic dermatitis; DNCB; keratinocytes; cytokines, inflammation

Ask authors/readers for more resources

The study showed that Rosa davurica Pall. leaves have significant anti-inflammatory effects on atopic dermatitis by reducing the release of inflammatory mediators, decreasing inflammation reactions, and modulating skin inflammation. This indicates that Rosa davurica Pall. may serve as a potential alternative therapeutic treatment for skin disorders like atopic dermatitis.
Purpose: Rosa davurica Pall., is mainly distributed in Korea, Japan, northeastern China, southeastern Siberia, and eastern Asia. It has been extensively used to treat various kinds of diseases by reason of the significant antioxidant, antiviral and anti-inflammatory activities. However, the pharmacological mechanism of Rosa davurica Pall. in atopic dermatitis (AD) is still ill defined and poorly understood. This study was to examine the antiinflammatory effects and its mechanism on AD of Rosa davurica Pall. leaves (RDL). Methods: To evaluate the therapeutic potential of RDL against AD, we have investigated the effects of RDL on the inflammatory reactions and the productions of inflammatory chemokines and cytokines that were induced by tumor necrosis factor-alpha (TNF-alpha)/interferon-gamma (IFN-gamma) in HaCaT cells. Futhermore, we examined the effects of RDL on the signaling pathways of mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-kappa B). For the in-vivo studies, RDL extract was topically applied to the dinitrochlorobenzene (DNCB)-induced AD mice, then its therapeutic effect was evaluated physiologically and morphologically. Results: After the stimulation of HaCaT cells with TNF-alpha/IFN-gamma, RDL considerably reduced the release of inflammatory mediators such as nitric oxide (NO), PEG2 and other cytokines. RDL also reduced the phosphorylations of MAPK and NF-kappa B in TNF-alpha/IFN-gamma-stimulated HaCaT cells. In vivo topical application of RDL to DNCBinduced AD mice significantly reduced the dorsal skin and ear thickness, clinical dermatitis severity, and mast cells. Treatment with RDL also markedly decreased the levels of serum IgE, IL-6 and the number of WBCs in the blood. Conclusion: Our studies indicate that RDL inhibits the AD-like skin lesions by modulating skin inflammation. Consequently, these results suggest that RDL may be served as a possible alternative therapeutic treatment for skin disorder such as AD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available